Ranitidine Market Size, Growth and SWOT Analysis by Key Players GlaxoSmithKline, Boehringer Ingelheim GmbH, Strides Pharma Science Limited, Tocris Bioscience

The Global Ranitidine Market, by Strength (75 mg, 150 mg, and 300 mg), by Form (Tablets, Syrup, and Injection), by Route of Administration (Oral and Intravenous), by Application (Intestinal & Stomach Ulcers, Gastroesophageal Reflux Disease (GERD), Esophagitis, Zollinger-Ellison Syndrome, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), was valued US$ 412.4 Mn in 2017, and is projected to exhibit a CAGR of 1.8% over the forecast period (2018 - 2026)

In May 2017, Strides Pharma Science Limited (Strides Shasun) and Vivimed Labs signed definitive agreement to set 50:50 joint venture to launch ranitidine tablet 150 mg in the U.S.

In February 2018, Strides Shasun launched Ranitidine Tablets USP, 150 mg in the U.S. market. Furthermore, in March 2018, company launched Ranitidine Tablets USP, 75 mg in the U.S. market. The new launch will strengthen Strides’ ranitidine portfolio in the U.S. ranitidine market.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/2131

Key takeaways of Ranitidine Market:

Among strength, ranitidine 150 mg tablet accounted for major market share in 2017. For stomach or intestinal ulcer and GERD, 150 mg dose twice daily or 300 mg dose at bedtime is normally taken. 150 mg tablet segment dominate the market, however preference to choose from 75 mg, 150 mg and 300 mg medication is depends on the patients therapeutic condition.

In form segment, tablet form hold major market share, owing to convenience and portability of tablet during daily routine

Among the route of administration, oral segment accounted to register higher market share, compared to intravenous, as intravenous administration requires proscription of healthcare professionals. Ranitidine can be taken in tablet or syrup form, orally.

Among application, intestinal and stomach ulcers segment held major market share in 2017. As stomach or intestinal ulcers are the most common type of ulcer associated with painful sores in the stomach lining, affecting stomach and small internes.

Among distribution channel, retail pharmacies segment held major market share in 2017. Retail pharmacies act as key channel in distribution of ranitidine medication to patients’ suffering with digestive diseases.

Healthcare professionals have been keenly interested in the treatment of gastroesophageal reflux disease (GERD) and stomach & intestinal ulcer owing to its increasing prevalence. GERD is common health problem, which leads to serious medical complications and further huge medical expense in its diagnosis and treatment. The two most frequently observed symptoms associated with GERD are heartburn and acid regurgitation. Usually, over-the-counter antacids, proton pump inhibitor, and H-2 receptor blockers are used to decrease the effects of stomach acids or to block acid production.

Ranitidine is a histamine H2 antagonists and available as both over-the-counter (OTC) and prescription drug, indicated in the treatment of gastroesophageal reflux disease (GERD). Ranitidine decreases the acid production from stomach for up to 12 hours. Also, ranitidine is commonly used in erosive esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome. It could be taken orally or intravenously.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2131

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave

This release was published on openPR.